Jakob Felding

Jakob Felding

Company: LEO Pharma

Job title: Director, Skin Research


Dr. Felding has 20 years of drug discovery experience. During this time he has worked in both midsize pharma companies and biotech. He has been involved in a variety of research topics such as target identification, target validation, hit identification technologies, medchem design, drug candidate selection, pipeline management and open innovation. Currently he is Sr. Director of Skin Research at LEO pharma, which is a biology function responsible for providing expert biology input across the pipeline projects and pre-clinical biology support from the early idea phase up to proof-of-concept in man. In addition, he is member of the management team in the Research organization at LEO Pharma. Dr. Felding has co-authored 44 publications and is a co-inventor of 33 patents.


Case Study by LEO Pharma: IL22R a new target for treatment of Atopic Dermatitis (AD) 11:15 am

• Studying the mechanisms being trialled for systemic treatment of AD • What is the pharmacological relevance of inhibiting IL22R for treatment of AD? • Examining the preclinical skin models used to evaluate IL22R as a new targetRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.